US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

FibroBiologics

1.44

+0.150011.63%

Post-market: 1.440.00000.00%19:30 EDT

Volume:570.61K

Turnover:812.10K

Market Cap:9.59M

PE:-0.30

High:1.49

Open:1.35

Low:1.34

Close:1.29

52wk High:12.80

52wk Low:0.6201

Shares:6.66M

Float Shares:5.84M

Volume Ratio:2.02

T/O Rate:9.77%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.7656

EPS(LYR):-8.3501

ROE:-660.08%

ROA:-95.77%

PB:2.07

PE(LYR):-0.17

Loading ...

Overview Company News Filings

Fibrobiologics Inc - to Initiate Discussions With Regulators for Hps Clinical Evaluation

THOMSON REUTERS

FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus

FibroBiologics boosts ATM equity offering capacity to USD 7.5 million

Fibrobiologics Inc - Increases Atm Offering to Aggregate $7.5 Mln on May 5, 2026 - SEC Filing

THOMSON REUTERS

FibroBiologics CEO Issues Letter to Shareholders

FibroBiologics Grants Stock Options to Key Executives

FibroBiologics grants CEO 92,410 stock options, executives 61,607 each at $1.38

FibroBiologics reports preclinical burn-wound data for fibroblast spheroid therapy

FibroBiologics Cut to Hold From Buy by Maxim Group

FibroBiologics releases CYWC628 drug product for Phase 1/2 diabetic foot ulcer trial

Fibrobiologics Inc - Phase 1/2 Trial to Evaluate Cywc628 Safety, Tolerability, and Efficacy in Dfu Patients

THOMSON REUTERS

Fibrobiologics Inc : Maxim Group Cuts to Hold From Buy

THOMSON REUTERS

FibroBiologics Warns of ‘Going Concern’ Risk as Losses Mount and Funding Outlook Darkens

FibroBiologics Launches New At-The-Market Equity Offering

FibroBiologics enters $6.15 million at-the-market equity offering agreement with H.C. Wainwright

Fibrobiologics Inc - Enters Atm Offering Agreement to Sell up to $6.15 Mln of Common Stock - SEC Filing

THOMSON REUTERS

FibroBiologics reports Q1 net loss roughly ($5M)

FibroBiologics, Inc. - Common Stock Q1 EPS $(1.33), Inline

Benzinga Earnings

FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update

Fibrobiologics Q1 net loss widens to $5 million; R&D expense climbs to $2.95 million

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/FBLG/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"FBLG","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FBLG\",,,,,undefined,":{"symbol":"FBLG","market":"US","secType":"STK","nameCN":"FibroBiologics","latestPrice":1.44,"timestamp":1787342400000,"preClose":1.29,"halted":0,"volume":570614,"hourTrading":{"tag":"盘后","latestPrice":1.44,"preClose":1.44,"latestTime":"19:30 EDT","volume":2511,"amount":3613.844,"timestamp":1787355006957,"change":0,"changeRate":0,"amplitude":0.006944},"delay":0,"changeRate":0.11627906976744179,"floatShares":5843116,"shares":6658193,"eps":-4.765638,"marketStatus":"Market Closed","change":0.15,"latestTime":"08-21 16:00:00 EDT","open":1.35,"high":1.4888,"low":1.34,"amount":812103.4368172,"amplitude":0.115349,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.765638,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"listingDate":1706677200000,"exchange":"NASDAQ","adjPreClose":1.29,"preHourTrading":{"tag":"盘前","latestPrice":1.35,"preClose":1.29,"latestTime":"09:29 EDT","volume":11237,"amount":15572.155941,"timestamp":1787318999999,"change":0.06,"changeRate":0.046512,"amplitude":0.062016},"postHourTrading":{"tag":"盘后","latestPrice":1.44,"preClose":1.44,"latestTime":"19:30 EDT","volume":2511,"amount":3613.844,"timestamp":1787355006957,"change":0,"changeRate":0,"amplitude":0.006944},"volumeRatio":2.023366365359968},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FBLG\",,,,,undefined,":{"symbol":"FBLG","floatShares":5843116,"roa":"-95.77%","roe":"-660.08%","lyrEps":-8.3501,"volumeRatio":2.023366365359968,"shares":6658193,"dividePrice":0,"high":1.4888,"amplitude":0.115349,"preClose":1.29,"low":1.34,"week52Low":0.62005,"pbRate":"2.07","week52High":12.8,"institutionHeld":0,"latestPrice":1.44,"eps":-4.765638,"divideRate":0,"volume":570614,"delay":0,"ttmEps":-4.765638,"open":1.35,"prevYearClose":4.498,"prevWeekClose":1.06,"prevMonthClose":0.7,"prevQuarterClose":0.9477,"fiveDayClose":1.06,"twentyDayClose":0.712,"sixtyDayClose":1.12},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/FBLG\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-07-31","symbol":"FBLG","fiscalQuarterEnding":"2026/06","expectedEps":-0.93,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1785470400000,"reportTimeType":"post","actualEps":-0.66},{"market":"US","date":"2026-04-30","symbol":"FBLG","fiscalQuarterEnding":"2026/03","expectedEps":-1.26,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1777521600000,"reportTimeType":"post","actualEps":-1.33},{"market":"US","date":"2026-03-30","symbol":"FBLG","defaultRemindTime":1774877400000,"type":"split","dateTimestamp":1774843200000,"forFactor":20,"toFactor":1,"ratio":20},{"market":"US","date":"2026-02-24","symbol":"FBLG","fiscalQuarterEnding":"2025/12","expectedEps":-0.09,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1771909200000,"reportTimeType":"post","actualEps":-0.03},{"market":"US","date":"2025-10-31","symbol":"FBLG","fiscalQuarterEnding":"2025/09","expectedEps":-0.1,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1761883200000,"reportTimeType":"post","actualEps":-0.13}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"FBLG\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"FBLG\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1777953600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/FBLG\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"FBLG","date":"2026-08-21","current":-0.302163,"percent":0.841935,"low":-68.573467,"twenty":-5.885273,"median":-2.907657,"eighty":-0.890492,"high":-0.181252,"avg":-5.889048,"sd":9.591455,"marketCap":8589068},"quantilePoints":[{"date":"2024-02-02","current":-68.573467,"twenty":-68.573467,"median":-68.573467,"eighty":-68.573467,"marketCap":568611190},{"date":"2024-02-09","current":-30.642544,"twenty":-58.777258,"median":-48.452053,"eighty":-34.01244,"marketCap":254087971},{"date":"2024-02-16","current":-50.313332,"twenty":-58.777258,"median":-50.313332,"eighty":-30.642544,"marketCap":417198153},{"date":"2024-02-23","current":-47.413654,"twenty":-56.896385,"median":-48.5892,"eighty":-33.338461,"marketCap":393154022},{"date":"2024-03-01","current":-25.741365,"twenty":-54.984165,"median":-48.491237,"eighty":-33.338461,"marketCap":424346408},{"date":"2024-03-08","current":-19.47356,"twenty":-53.244359,"median":-47.492024,"eighty":-25.717713,"marketCap":321021631},{"date":"2024-03-15","current":-20.892685,"twenty":-51.363486,"median":-37.245189,"eighty":-20.955758,"marketCap":344415920},{"date":"2024-03-22","current":-23.849198,"twenty":-50.446561,"median":-28.99678,"eighty":-20.813845,"marketCap":393154022},{"date":"2024-03-28","current":-23.159345,"twenty":-50.219289,"median":-25.741365,"eighty":-20.93999,"marketCap":381781799},{"date":"2024-04-05","current":-22.469492,"twenty":-49.216157,"median":-24.637601,"eighty":-21.160743,"marketCap":370409575},{"date":"2024-04-12","current":-22.311811,"twenty":-48.471645,"median":-23.652097,"eighty":-21.298713,"marketCap":367810209},{"date":"2024-04-19","current":-21.700799,"twenty":-48.064123,"median":-23.20862,"eighty":-21.030656,"marketCap":357737668},{"date":"2024-04-26","current":-23.021374,"twenty":-47.63309,"median":-22.804563,"eighty":-21.030656,"marketCap":379507354},{"date":"2024-05-03","current":-13.245174,"twenty":-47.445002,"median":-22.479347,"eighty":-20.675875,"marketCap":218346696},{"date":"2024-05-10","current":-17.22661,"twenty":-43.252224,"median":-22.05558,"eighty":-19.871704,"marketCap":283980674},{"date":"2024-05-17","current":-17.017594,"twenty":-36.598639,"median":-21.769784,"eighty":-19.221271,"marketCap":383406402},{"date":"2024-05-24","current":-16.310932,"twenty":-31.990502,"median":-21.661379,"eighty":-18.255477,"marketCap":367485289},{"date":"2024-05-31","current":-17.767522,"twenty":-29.984238,"median":-21.543118,"eighty":-17.827098,"marketCap":400302277},{"date":"2024-06-07","current":-14.972667,"twenty":-28.19741,"median":-21.306597,"eighty":-17.252609,"marketCap":337334178},{"date":"2024-06-14","current":-10.427133,"twenty":-26.746956,"median":-21.178482,"eighty":-16.659936,"marketCap":234923317},{"date":"2024-06-21","current":-7.769521,"twenty":-25.741365,"median":-20.932105,"eighty":-16.368618,"marketCap":175047318},{"date":"2024-06-28","current":-6.767471,"twenty":-25.694061,"median":-20.88283,"eighty":-16.302279,"marketCap":152471122},{"date":"2024-07-05","current":-6.143005,"twenty":-25.43783,"median":-20.64631,"eighty":-15.81876,"marketCap":138401898},{"date":"2024-07-12","current":-7.689204,"twenty":-24.673079,"median":-20.183123,"eighty":-14.136173,"marketCap":173237756},{"date":"2024-07-15","current":-7.514809,"twenty":-24.649427,"median":-20.094427,"eighty":-13.517924,"marketCap":169308652},{"date":"2024-08-02","current":-7.974576,"twenty":-24.625775,"median":-20.005732,"eighty":-13.175194,"marketCap":179667198},{"date":"2024-08-09","current":-4.080921,"twenty":-24.140907,"median":-19.700225,"eighty":-10.836667,"marketCap":79459622},{"date":"2024-08-16","current":-2.166861,"twenty":-23.730937,"median":-18.842837,"eighty":-9.439605,"marketCap":42190950},{"date":"2024-08-23","current":-2.546062,"twenty":-23.640271,"median":-18.638558,"eighty":-7.79743,"marketCap":49574366},{"date":"2024-08-30","current":-2.915474,"twenty":-23.407692,"median":-18.172694,"eighty":-7.552859,"marketCap":56767191},{"date":"2024-09-06","current":-3.368187,"twenty":-23.218475,"median":-17.767522,"eighty":-6.924314,"marketCap":65581972},{"date":"2024-09-13","current":-5.722296,"twenty":-23.104157,"median":-17.428613,"eighty":-6.143005,"marketCap":111418835},{"date":"2024-09-20","current":-5.722296,"twenty":-22.93465,"median":-17.22661,"eighty":-5.90745,"marketCap":111418835},{"date":"2024-09-27","current":-5.686079,"twenty":-22.765143,"median":-16.563311,"eighty":-5.873037,"marketCap":110713652},{"date":"2024-10-04","current":-4.798761,"twenty":-22.619289,"median":-16.368618,"eighty":-5.722296,"marketCap":93436681},{"date":"2024-10-11","current":-4.20118,"twenty":-22.481318,"median":-16.080185,"eighty":-5.265962,"marketCap":81801170},{"date":"2024-10-18","current":-6.012033,"twenty":-22.40642,"median":-15.807485,"eighty":-5.066768,"marketCap":117060295},{"date":"2024-10-25","current":-5.215258,"twenty":-22.209319,"median":-15.237992,"eighty":-5.131958,"marketCap":101546280},{"date":"2024-10-31","current":-5.342017,"twenty":-22.020102,"median":-13.586112,"eighty":-5.110228,"marketCap":104014418},{"date":"2024-11-08","current":-6.464746,"twenty":-21.866364,"median":-12.649071,"eighty":-5.128337,"marketCap":125875076},{"date":"2024-11-15","current":-5.477931,"twenty":-21.799349,"median":-10.768411,"eighty":-5.146445,"marketCap":97392141},{"date":"2024-11-22","current":-4.698155,"twenty":-21.716567,"median":-9.773622,"eighty":-5.018763,"marketCap":83528491},{"date":"2024-11-29","current":-5.107537,"twenty":-21.700799,"median":-9.003931,"eighty":-5.016064,"marketCap":90806907},{"date":"2024-12-06","current":-4.639671,"twenty":-21.661379,"median":-7.895306,"eighty":-4.997955,"marketCap":82488717},{"date":"2024-12-13","current":-4.425233,"twenty":-21.562828,"median":-7.720912,"eighty":-4.979847,"marketCap":78676213},{"date":"2024-12-20","current":-3.957367,"twenty":-21.543118,"median":-7.546517,"eighty":-4.853087,"marketCap":70358023},{"date":"2024-12-27","current":-4.50321,"twenty":-21.511582,"median":-7.203145,"eighty":-4.778145,"marketCap":80062578},{"date":"2025-01-03","current":-3.869642,"twenty":-21.385437,"median":-6.905845,"eighty":-4.698155,"marketCap":68798363},{"date":"2025-01-10","current":-4.065278,"twenty":-21.306597,"median":-6.609614,"eighty":-4.652603,"marketCap":72276579},{"date":"2025-01-17","current":-3.769263,"twenty":-21.298713,"median":-6.286711,"eighty":-4.50321,"marketCap":67013721},{"date":"2025-01-24","current":-3.157497,"twenty":-21.243525,"median":-6.193118,"eighty":-4.433031,"marketCap":56137148},{"date":"2025-01-31","current":-3.295638,"twenty":-21.050366,"median":-6.140899,"eighty":-4.36675,"marketCap":58593149},{"date":"2025-02-07","current":-3.157497,"twenty":-20.955758,"median":-6.004281,"eighty":-4.203103,"marketCap":56137148},{"date":"2025-02-14","current":-2.545732,"twenty":-20.888743,"median":-5.948653,"eighty":-4.068407,"marketCap":45260576},{"date":"2025-02-21","current":-2.447061,"twenty":-20.872975,"median":-5.908467,"eighty":-3.946872,"marketCap":43506290},{"date":"2025-02-28","current":-2.348389,"twenty":-20.794135,"median":-5.885273,"eighty":-3.784683,"marketCap":41752004},{"date":"2025-03-07","current":-2.210248,"twenty":-20.498484,"median":-5.867165,"eighty":-3.670591,"marketCap":39296004},{"date":"2025-03-14","current":-2.109947,"twenty":-20.183123,"median":-5.776622,"eighty":-3.453513,"marketCap":37512750},{"date":"2025-03-21","current":-2.151728,"twenty":-20.183123,"median":-5.722296,"eighty":-3.368187,"marketCap":38255577},{"date":"2025-03-28","current":-2.130838,"twenty":-20.005732,"median":-5.595537,"eighty":-3.295638,"marketCap":37884163},{"date":"2025-04-04","current":-2.958372,"twenty":-19.926892,"median":-5.518575,"eighty":-3.165965,"marketCap":33018387},{"date":"2025-04-11","current":-2.748074,"twenty":-19.788921,"median":-5.342017,"eighty":-3.105834,"marketCap":30671251},{"date":"2025-04-17","current":-3.685286,"twenty":-19.647008,"median":-5.282987,"eighty":-3.104326,"marketCap":41131477},{"date":"2025-04-25","current":-4.361485,"twenty":-19.501154,"median":-5.215258,"eighty":-3.131377,"marketCap":48678537},{"date":"2025-05-02","current":-3.496805,"twenty":-18.968982,"median":-5.142823,"eighty":-3.15355,"marketCap":39027837},{"date":"2025-05-09","current":-2.900977,"twenty":-18.732461,"median":-5.107537,"eighty":-3.105179,"marketCap":32377800},{"date":"2025-05-16","current":-5.090366,"twenty":-18.693381,"median":-5.090366,"eighty":-3.095239,"marketCap":39027837},{"date":"2025-05-23","current":-4.291877,"twenty":-18.607387,"median":-5.049055,"eighty":-3.101704,"marketCap":32905823},{"date":"2025-05-30","current":-3.742916,"twenty":-18.421041,"median":-5.00701,"eighty":-3.104523,"marketCap":28696939},{"date":"2025-06-06","current":-4.262932,"twenty":-18.227882,"median":-4.979847,"eighty":-3.124991,"marketCap":32683900},{"date":"2025-06-13","current":-4.354259,"twenty":-18.018955,"median":-4.934576,"eighty":-3.149603,"marketCap":33384106},{"date":"2025-06-20","current":-3.674878,"twenty":-17.856887,"median":-4.868731,"eighty":-3.157497,"marketCap":28175292},{"date":"2025-06-27","current":-3.644169,"twenty":-17.748258,"median":-4.815121,"eighty":-3.160884,"marketCap":27939844},{"date":"2025-07-03","current":-3.132347,"twenty":-17.688614,"median":-4.795627,"eighty":-3.157497,"marketCap":24015708},{"date":"2025-07-11","current":-3.321721,"twenty":-17.510817,"median":-4.711647,"eighty":-3.13343,"marketCap":25467638},{"date":"2025-07-18","current":-3.531568,"twenty":-17.278608,"median":-4.698155,"eighty":-3.14171,"marketCap":27076534},{"date":"2025-07-25","current":-3.36062,"twenty":-17.22661,"median":-4.675331,"eighty":-3.157497,"marketCap":25765873},{"date":"2025-08-01","current":-3.260303,"twenty":-17.184807,"median":-4.665775,"eighty":-3.157497,"marketCap":24996742},{"date":"2025-08-08","current":-1.692292,"twenty":-16.92818,"median":-4.639671,"eighty":-3.111465,"marketCap":22377179},{"date":"2025-08-15","current":-1.862725,"twenty":-16.567638,"median":-4.558872,"eighty":-3.098103,"marketCap":24630815},{"date":"2025-08-22","current":-1.865576,"twenty":-16.533025,"median":-4.524553,"eighty":-3.074912,"marketCap":24668515},{"date":"2025-08-29","current":-1.964732,"twenty":-16.426305,"median":-4.50321,"eighty":-3.015849,"marketCap":25979645},{"date":"2025-09-05","current":-1.881416,"twenty":-16.368618,"median":-4.425233,"eighty":-2.962429,"marketCap":24877961},{"date":"2025-09-12","current":-1.789547,"twenty":-16.310932,"median":-4.376497,"eighty":-2.933582,"marketCap":23663176},{"date":"2025-09-19","current":-1.694826,"twenty":-16.29651,"median":-4.361485,"eighty":-2.897365,"marketCap":22410690},{"date":"2025-09-26","current":-1.709716,"twenty":-15.863859,"median":-4.348021,"eighty":-2.853034,"marketCap":22607569},{"date":"2025-10-03","current":-1.710666,"twenty":-15.863859,"median":-4.327761,"eighty":-2.748074,"marketCap":22620136},{"date":"2025-10-10","current":-1.544034,"twenty":-15.807485,"median":-4.261494,"eighty":-2.486529,"marketCap":20416767},{"date":"2025-10-17","current":-1.298839,"twenty":-15.630094,"median":-4.210794,"eighty":-2.348389,"marketCap":17174548},{"date":"2025-10-24","current":-1.301056,"twenty":-15.503317,"median":-4.186877,"eighty":-2.318853,"marketCap":17203870},{"date":"2025-10-31","current":-1.257339,"twenty":-14.972667,"median":-4.132817,"eighty":-2.297962,"marketCap":16625800},{"date":"2025-11-07","current":-0.932278,"twenty":-13.927049,"median":-4.072247,"eighty":-2.249717,"marketCap":17248077},{"date":"2025-11-14","current":-0.933669,"twenty":-13.245174,"median":-4.04235,"eighty":-2.172619,"marketCap":17273805},{"date":"2025-11-21","current":-0.902797,"twenty":-13.070223,"median":-4.004863,"eighty":-2.130838,"marketCap":16702642},{"date":"2025-11-28","current":-0.907742,"twenty":-12.733301,"median":-3.95212,"eighty":-2.105769,"marketCap":16794130},{"date":"2025-12-05","current":-0.861361,"twenty":-11.417566,"median":-3.918378,"eighty":-2.038689,"marketCap":15936036},{"date":"2025-12-12","current":-1.151904,"twenty":-11.10969,"median":-3.880347,"eighty":-1.962831,"marketCap":21311383},{"date":"2025-12-19","current":-0.864342,"twenty":-10.563644,"median":-3.855551,"eighty":-1.925449,"marketCap":15991199},{"date":"2025-12-26","current":-0.781519,"twenty":-10.366139,"median":-3.817676,"eighty":-1.905048,"marketCap":14458888},{"date":"2026-01-02","current":-0.80862,"twenty":-10.104734,"median":-3.784683,"eighty":-1.867667,"marketCap":14960285},{"date":"2026-01-09","current":-1.186504,"twenty":-9.756195,"median":-3.726488,"eighty":-1.863485,"marketCap":21951508},{"date":"2026-01-16","current":-1.21347,"twenty":-9.439605,"median":-3.689721,"eighty":-1.817994,"marketCap":22450406},{"date":"2026-01-23","current":-1.222459,"twenty":-8.832939,"median":-3.685286,"eighty":-1.804182,"marketCap":22616705},{"date":"2026-01-30","current":-1.226773,"twenty":-8.114091,"median":-3.670176,"eighty":-1.745069,"marketCap":22696529},{"date":"2026-02-06","current":-0.81653,"twenty":-7.942868,"median":-3.64061,"eighty":-1.71998,"marketCap":15106628},{"date":"2026-02-13","current":-0.884485,"twenty":-7.806733,"median":-3.5628,"eighty":-1.705851,"marketCap":16363851},{"date":"2026-02-20","current":-0.903181,"twenty":-7.769521,"median":-3.544415,"eighty":-1.692292,"marketCap":16709754},{"date":"2026-02-27","current":-1.025558,"twenty":-7.720912,"median":-3.492982,"eighty":-1.665999,"marketCap":19122546},{"date":"2026-03-06","current":-1.519667,"twenty":-7.689204,"median":-3.463009,"eighty":-1.553538,"marketCap":28335707},{"date":"2026-03-13","current":-1.232917,"twenty":-7.578225,"median":-3.43637,"eighty":-1.519667,"marketCap":22988964},{"date":"2026-03-20","current":-0.927678,"twenty":-7.514809,"median":-3.414459,"eighty":-1.43094,"marketCap":17297489},{"date":"2026-03-27","current":-0.797535,"twenty":-7.246713,"median":-3.39431,"eighty":-1.385333,"marketCap":14870838},{"date":"2026-04-02","current":-0.241073,"twenty":-7.177005,"median":-3.378022,"eighty":-1.359957,"marketCap":4495048},{"date":"2026-04-10","current":-0.336129,"twenty":-7.067291,"median":-3.359084,"eighty":-1.328997,"marketCap":6267453},{"date":"2026-04-17","current":-0.370229,"twenty":-6.822821,"median":-3.321721,"eighty":-1.299599,"marketCap":6903282},{"date":"2026-04-24","current":-0.367793,"twenty":-6.742593,"median":-3.30892,"eighty":-1.267223,"marketCap":6857865},{"date":"2026-05-01","current":-0.368753,"twenty":-6.533559,"median":-3.275657,"eighty":-1.232416,"marketCap":6875767},{"date":"2026-05-08","current":-0.345774,"twenty":-6.468368,"median":-3.258236,"eighty":-1.221308,"marketCap":6459054},{"date":"2026-05-15","current":-0.312154,"twenty":-6.322318,"median":-3.235952,"eighty":-1.201893,"marketCap":5831040},{"date":"2026-05-22","current":-0.303483,"twenty":-6.255297,"median":-3.19076,"eighty":-1.171044,"marketCap":5669067},{"date":"2026-05-29","current":-0.326606,"twenty":-6.214848,"median":-3.171598,"eighty":-1.119059,"marketCap":6100996},{"date":"2026-06-05","current":-0.309264,"twenty":-6.16305,"median":-3.157497,"eighty":-1.023143,"marketCap":5777049},{"date":"2026-06-12","current":-0.278626,"twenty":-6.143005,"median":-3.135055,"eighty":-0.995266,"marketCap":5204743},{"date":"2026-06-18","current":-0.231225,"twenty":-6.14132,"median":-3.119296,"eighty":-0.966672,"marketCap":4319289},{"date":"2026-06-26","current":-0.211918,"twenty":-6.088089,"median":-3.102557,"eighty":-0.949468,"marketCap":3958628},{"date":"2026-07-02","current":-0.261949,"twenty":-6.010483,"median":-3.098055,"eighty":-0.939027,"marketCap":4893215},{"date":"2026-07-10","current":-0.248856,"twenty":-6.001989,"median":-3.08079,"eighty":-0.932373,"marketCap":4648635},{"date":"2026-07-17","current":-0.242729,"twenty":-5.989422,"median":-3.058826,"eighty":-0.919078,"marketCap":4534174},{"date":"2026-07-24","current":-0.212583,"twenty":-5.964951,"median":-3.025992,"eighty":-0.912766,"marketCap":3971046},{"date":"2026-07-31","current":-0.207872,"twenty":-5.92149,"median":-2.981001,"eighty":-0.907742,"marketCap":3883041},{"date":"2026-08-07","current":-0.374406,"twenty":-5.913552,"median":-2.958372,"eighty":-0.904979,"marketCap":6791356},{"date":"2026-08-14","current":-0.422125,"twenty":-5.903382,"median":-2.937355,"eighty":-0.902462,"marketCap":7656921},{"date":"2026-08-21","current":-0.473514,"twenty":-5.885273,"median":-2.907657,"eighty":-0.890492,"marketCap":8589068}],"updateTime":1787445944529},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"FBLG\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2634289780","title":"Fibrobiologics Inc - to Initiate Discussions With Regulators for Hps Clinical Evaluation","url":"https://stock-news.laohu8.com/highlight/detail?id=2634289780","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634289780?lang=en_us&edition=fundamental","pubTime":"2026-05-11 20:30","pubTimestamp":1778502621,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nFWN41O10T:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","FBLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634928111","title":"FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus","url":"https://stock-news.laohu8.com/highlight/detail?id=2634928111","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634928111?lang=en_us&edition=fundamental","pubTime":"2026-05-11 20:30","pubTimestamp":1778502600,"startTime":"0","endTime":"0","summary":"Will Apply Existing Preclinical Findings in Reducing Severe Immune-Mediated Lung Failure to Potential Emerging Global CrisisHOUSTON, May  11, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBL","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/11/3291882/0/en/FibroBiologics-Advancing-Development-of-a-Fibroblast-Treatment-for-Hantavirus.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARDS","FBLG","BK4139","HPS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633878981","title":"FibroBiologics boosts ATM equity offering capacity to USD 7.5 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633878981","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633878981?lang=en_us&edition=fundamental","pubTime":"2026-05-06 19:17","pubTimestamp":1778066236,"startTime":"0","endTime":"0","summary":"FibroBiologics entered at-the-market equity distribution agreement with H.C. Wainwright, allowing sales of common stock from time to time under shelf registration statement.Prospectus supplement increased maximum size of ATM program to aggregate offering price of up to $7.5 million.71,830 shares have been sold under sales agreement to date.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 06, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nNDL3Cqfl3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FBLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633829511","title":"Fibrobiologics Inc - Increases Atm Offering to Aggregate $7.5 Mln on May 5, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2633829511","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633829511?lang=en_us&edition=fundamental","pubTime":"2026-05-06 19:07","pubTimestamp":1778065628,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nFWN41J0VE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","FBLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633484249","title":"FibroBiologics CEO Issues Letter to Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2633484249","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633484249?lang=en_us&edition=fundamental","pubTime":"2026-05-05 20:30","pubTimestamp":1777984200,"startTime":"0","endTime":"0","summary":"HOUSTON, May  05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the devel","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/05/3287694/0/en/FibroBiologics-CEO-Issues-Letter-to-Shareholders.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633103499","title":"FibroBiologics Grants Stock Options to Key Executives","url":"https://stock-news.laohu8.com/highlight/detail?id=2633103499","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633103499?lang=en_us&edition=fundamental","pubTime":"2026-05-05 20:01","pubTimestamp":1777982460,"startTime":"0","endTime":"0","summary":"FibroBiologics, Inc. ( ($FBLG) ) has issued an update. On May 4, 2026, FibroBiologics, Inc.’s compensation committee granted stock options under it...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/fibrobiologics-grants-stock-options-to-key-executives?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/fibrobiologics-grants-stock-options-to-key-executives?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FBLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633177912","title":"FibroBiologics grants CEO 92,410 stock options, executives 61,607 each at $1.38","url":"https://stock-news.laohu8.com/highlight/detail?id=2633177912","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633177912?lang=en_us&edition=fundamental","pubTime":"2026-05-05 19:22","pubTimestamp":1777980120,"startTime":"0","endTime":"0","summary":"FibroBiologics granted stock options under its 2022 Stock Plan to CEO Pete O’Heeron for 92,410 common shares, with an exercise price of $1.38 per share.Options covering 61,607 shares each were also issued to CFO Jason D. Davis, Chief Scientific Officer Hamid Khoja, and General Counsel Ruben A. Garcia at the same $1.38 strike.Vesting starts with 25% on first anniversary of May 4, 2026 grant date.Remaining options vest in 36 equal monthly installments, contingent on continued service.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commissi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nNDL6w8q00:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FBLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633634869","title":"FibroBiologics reports preclinical burn-wound data for fibroblast spheroid therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2633634869","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633634869?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:03","pubTimestamp":1777924991,"startTime":"0","endTime":"0","summary":"FibroBiologics disclosed preclinical burn-wound data already presented, pointing to a rapid shift in wound biology following topical treatment with human dermal fibroblast spheroids.Treated wounds appeared less inflamed, with signs of immune activity moving toward tissue repair rather than persistent inflammation.Biomarker readouts also suggested reduced scar-forming activity, supporting a potential positioning in burn care where long-term scarring drives clinical burden.Management framed results as mechanistic support to expand its wound-care platform to include burn injuries, signaling a broader development strategy beyond core indications.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDL8NsGsq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU2095319765.USD","LU2210149790.SGD","IE00BKPKM429.USD","SG9999014013.SGD","IE00BGHQF748.EUR","IE00BN0W2V16.EUR","LU0314104364.USD","SG9999014039.USD","BK4588","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","SG9999014005.SGD","NDAQ","IE00BN0W2W23.USD","IE00B64PRP62.GBP","BK4139","FBLG","SG9999014021.USD","BK4112","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632955165","title":"FibroBiologics Cut to Hold From Buy by Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2632955165","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632955165?lang=en_us&edition=fundamental","pubTime":"2026-05-04 21:04","pubTimestamp":1777899840,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/FBLG/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 04, 2026 09:04 ET (13:04 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632923953","title":"FibroBiologics releases CYWC628 drug product for Phase 1/2 diabetic foot ulcer trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2632923953","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632923953?lang=en_us&edition=fundamental","pubTime":"2026-05-04 20:33","pubTimestamp":1777897987,"startTime":"0","endTime":"0","summary":"FibroBiologics released first cGMP batch of investigational CYWC628 drug product to support planned Phase 1/2 clinical trial in diabetic foot ulcers.Batch cleared required safety and quality testing, enabling clinical use and allowing patient enrollment to start.No clinical results have been presented; trial will assess safety, tolerability, and early signs of benefit.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDLBxjLM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","SG9999014005.SGD","IE00BKPKM429.USD","BK4588","LU0314104364.USD","LU2095319765.USD","BK4585","BK4139","FBLG","IE00BN0W2V16.EUR","LU2210150020.SGD","NDAQ","SG9999014013.SGD","IE00B3QW5Z07.USD","BK4112","IE00BN0W2W23.USD","SG9999014039.USD","SG9999014021.USD","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632953674","title":"Fibrobiologics Inc - Phase 1/2 Trial to Evaluate Cywc628 Safety, Tolerability, and Efficacy in Dfu Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2632953674","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632953674?lang=en_us&edition=fundamental","pubTime":"2026-05-04 20:30","pubTimestamp":1777897800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nTUA9QQG20:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FBLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632953801","title":"Fibrobiologics Inc : Maxim Group  Cuts to Hold From Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2632953801","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632953801?lang=en_us&edition=fundamental","pubTime":"2026-05-04 20:18","pubTimestamp":1777897090,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nFWN41H0QT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FBLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632162211","title":"FibroBiologics Warns of ‘Going Concern’ Risk as Losses Mount and Funding Outlook Darkens","url":"https://stock-news.laohu8.com/highlight/detail?id=2632162211","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632162211?lang=en_us&edition=fundamental","pubTime":"2026-05-02 14:01","pubTimestamp":1777701683,"startTime":"0","endTime":"0","summary":"FibroBiologics, Inc. (FBLG) has disclosed a new risk, in the Corporate Activity and Growth category. FibroBiologics, Inc. faces substantial doubt a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/fibrobiologics-warns-of-going-concern-risk-as-losses-mount-and-funding-outlook-darkens?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/fibrobiologics-warns-of-going-concern-risk-as-losses-mount-and-funding-outlook-darkens?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FBLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632628692","title":"FibroBiologics Launches New At-The-Market Equity Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2632628692","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632628692?lang=en_us&edition=fundamental","pubTime":"2026-05-02 05:08","pubTimestamp":1777669685,"startTime":"0","endTime":"0","summary":"The latest announcement is out from FibroBiologics, Inc. ( ($FBLG) ). On May 1, 2026, FibroBiologics, Inc. entered into an at-the-market offering a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/fibrobiologics-launches-new-at-the-market-equity-offering?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/fibrobiologics-launches-new-at-the-market-equity-offering?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","EQR","BK4215","BK4588","FBLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632642269","title":"FibroBiologics enters $6.15 million at-the-market equity offering agreement with H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2632642269","media":"Reuters","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632642269?lang=en_us&edition=fundamental","pubTime":"2026-05-02 04:02","pubTimestamp":1777665747,"startTime":"0","endTime":"0","summary":"FibroBiologics entered at-the-market offering agreement with H.C. Wainwright to sell up to USD 6.15 million of common stock.Net proceeds expected to support working capital needs or general corporate purposes.Sales agent to receive 3% of gross sales proceeds.Company agreed to reimburse up to USD 100,000 of legal fees tied to agreement setup.Program can end once full USD 6.15 million is sold or if sales agreement is terminated.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 01, 2026, and is solely responsible for the i","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nNDL6kG9rT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632642256","title":"Fibrobiologics Inc - Enters Atm Offering Agreement to Sell up to $6.15 Mln of Common Stock - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2632642256","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632642256?lang=en_us&edition=fundamental","pubTime":"2026-05-02 04:02","pubTimestamp":1777665735,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nFWN41D1U9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FBLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632666277","title":"FibroBiologics reports Q1 net loss roughly ($5M)","url":"https://stock-news.laohu8.com/highlight/detail?id=2632666277","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632666277?lang=en_us&edition=fundamental","pubTime":"2026-05-01 06:00","pubTimestamp":1777586427,"startTime":"0","endTime":"0","summary":"The net loss for the three months ended March 31, 2026, was primarily due to research and development expenses and general and administrative expen...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fibrobiologics-reports-q1-net-loss-roughly-5m-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fibrobiologics-reports-q1-net-loss-roughly-5m-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","FBLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632662236","title":"FibroBiologics, Inc. - Common Stock Q1 EPS $(1.33), Inline","url":"https://stock-news.laohu8.com/highlight/detail?id=2632662236","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632662236?lang=en_us&edition=fundamental","pubTime":"2026-05-01 05:57","pubTimestamp":1777586270,"startTime":"0","endTime":"0","summary":"FibroBiologics, Inc. - Common Stock Q1 EPS $(1.33), Inline","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/quote/FBLG","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"FibroBiologics, Inc. - Common Stock Q1 EPS $(1.33), Inline","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632622646","title":"FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2632622646","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632622646?lang=en_us&edition=fundamental","pubTime":"2026-05-01 05:55","pubTimestamp":1777586100,"startTime":"0","endTime":"0","summary":"On track for first patient dosed in phase 1/2 clinical trial evaluating CYWC628 in diabetic foot ulcers in Q2 of 2026HOUSTON, April  30, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/30/3285584/0/en/FibroBiologics-Reports-Q1-2026-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632460662","title":"Fibrobiologics Q1 net loss widens to $5 million; R&D expense climbs to $2.95 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2632460662","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632460662?lang=en_us&edition=fundamental","pubTime":"2026-05-01 05:53","pubTimestamp":1777586022,"startTime":"0","endTime":"0","summary":"Fibrobiologics posted a net loss of USD 5 million for the three months ended March 31, 2026.Research and development expense climbed to USD 2.95 million, while general, administrative and other costs fell to USD 2.12 million.Cash and cash equivalents totaled USD 1.5 million as of March 31, 2026, with net cash used in operating activities of USD 4.36 million.Pipeline update: CYWC628 diabetic foot ulcer Phase 1/2 trial in Australia expected to start screening, enrollment and dosing in Q2 2026, with interim data expected in Q3 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system opera","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDL7dtNsR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":4,"totalSize":136,"code":"91000000","status":"200"}]}}